Home >> Professional Blog
MiMedx Group, Inc. (NASDAQ: MDXG) has entered into a distribution agreement with Medtronic, Inc. Through the agreement, MiMedx will provide its PURIONŽ processed allograft products to Medtronic to be marketed by SpinalGraft Technologies, LLC ("SGT") for spinal applications.
The MiMedx PURIONŽ processed allograft products distributed to Medtronic will be private-labeled. SGT will promote, market and sell the private-labeled allografts to its customers and end-users through-out the United States.
Mr. Pete Petit said, "This agreement is a significant milestone for MiMedx in expanding our customer base and broadening the breadth of physicians and patients with access to our PURIONŽ processed allografts. By partnering with Medtronic, many additional physicians and patients can be served through the extensive distribution arm and presence that Medtronic has in the spinal surgery market."
The $3.1 billion Spine business segment of Medtronic is developing many of the new standards of care in spinal and musculoskeletal therapies. Medtronic collaborates with world-renowned surgeons, researchers, and innovative partners to offer a broad range of state-of-the-art products and technologies that return patients to normal active lives more quickly, and treat a variety of musculoskeletal, neurological, orthopedic, and spinal conditions.
"We are very excited about our relationship with Medtronic," said Bill Taylor, MiMedx President and COO. "Medtronic has done an extraordinary job in serving the needs of practicing physicians. With the growing demand for an offering that can deliver the outcomes achieved by our PURIONŽ processed allografts, it is critical to align with a partner that has unparalleled respect among physicians and extensive relationships in this sector of healthcare."